Clinical trials: Diffuse Large B Cell Lymphoma, Gene Mutation, open to volunteers
Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+…
- Trial name
- NCT06846463
- Testing
- Zanubrutinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Virginia Commonwealth University
DLBCL
CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
This was an open, multicenter clinical study of newly treated DLBCL patients with TP53 mutations and del(17p) with IPI>1. Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of…
- Trial name
- NCT06750991
- Testing
- CDR-CHOP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Diffuse Large B-Cell Lymphoma (DLBCL)
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.
- Trial name
- NCT07499271
- Testing
- POLA-R-CHP, Orelabrutinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma。The majority of refractory patients have PD-L1 expression due to P53 mutations, some of which account for about 10% of DLBCL.Our department has found that…
- Trial name
- NCT05280626
- Testing
- Sintilimab, Rituximab
- Volunteers
- 100 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.